Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity
Sponsor: Eli Lilly
Indication: CVD and CKD Outcomes in patients with Obesity
GFR: 21-75
Principal Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246